Literature DB >> 33446253

Exome sequencing in paediatric patients with movement disorders.

Anna Ka-Yee Kwong1, Mandy Ho-Yin Tsang1, Jasmine Lee-Fong Fung1, Christopher Chun-Yu Mak1, Kate Lok-San Chan1, Richard J T Rodenburg2, Monkol Lek3, Shushu Huang3,4,5, Sander Pajusalu3,6,7, Man-Mut Yau8, Cheung Tsoi9, Sharon Fung10, Kam-Tim Liu11, Che-Kwan Ma12, Sheila Wong13, Eric Kin-Cheong Yau14, Shuk-Mui Tai11, Eva Lai-Wah Fung15, Nick Shun-Ping Wu16, Li-Yan Tsung11, Jan Smeitink2, Brian Hon-Yin Chung17,18,19,20,21, Cheuk-Wing Fung22,23.   

Abstract

BACKGROUND: Movement disorders are a group of heterogeneous neurological diseases including hyperkinetic disorders with unwanted excess movements and hypokinetic disorders with reduction in the degree of movements. The objective of our study is to investigate the genetic etiology of a cohort of paediatric patients with movement disorders by whole exome sequencing and to review the potential treatment implications after a genetic diagnosis.
RESULTS: We studied a cohort of 31 patients who have paediatric-onset movement disorders with unrevealing etiologies. Whole exome sequencing was performed and rare variants were interrogated for pathogenicity. Genetic diagnoses have been confirmed in 10 patients with disease-causing variants in CTNNB1, SPAST, ATP1A3, PURA, SLC2A1, KMT2B, ACTB, GNAO1 and SPG11. 80% (8/10) of patients with genetic diagnosis have potential treatment implications and treatments have been offered to them. One patient with KMT2B dystonia showed clinical improvement with decrease in dystonia after receiving globus pallidus interna deep brain stimulation.
CONCLUSIONS: A diagnostic yield of 32% (10/31) was reported in our cohort and this allows a better prediction of prognosis and contributes to a more effective clinical management. The study highlights the potential of implementing precision medicine in the patients.

Entities:  

Keywords:  Genetic diagnosis; Movement disorders; Treatment; Whole exome sequencing

Mesh:

Substances:

Year:  2021        PMID: 33446253      PMCID: PMC7809769          DOI: 10.1186/s13023-021-01688-6

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  33 in total

Review 1.  Using the shared genetics of dystonia and ataxia to unravel their pathogenesis.

Authors:  Esther A R Nibbeling; Cathérine C S Delnooz; Tom J de Koning; Richard J Sinke; Hyder A Jinnah; Marina A J Tijssen; Dineke S Verbeek
Journal:  Neurosci Biobehav Rev       Date:  2017-01-28       Impact factor: 8.989

Review 2.  Molecular mechanisms of go signaling.

Authors:  Meisheng Jiang; Neil S Bajpayee
Journal:  Neurosignals       Date:  2009-02-12

3.  Rationale for dopa-responsive CTNNB1/ß-catenin deficient dystonia.

Authors:  Judy Pipo-Deveza; Darcy Fehlings; David Chitayat; Grace Yoon; Hana Sroka; Ingrid Tein
Journal:  Mov Disord       Date:  2018-02-13       Impact factor: 10.338

4.  Dystonia-deafness syndrome caused by a β-actin gene mutation and response to deep brain stimulation.

Authors:  Hendriekje Eggink; Martje E van Egmond; Corien C Verschuuren-Bemelmans; Marleen C Schönherr; Tom J de Koning; D L Marinus Oterdoom; J Marc C van Dijk; Marina A J Tijssen
Journal:  Mov Disord       Date:  2016-11-08       Impact factor: 10.338

Review 5.  The glucose transporter type 1 (Glut1) syndromes.

Authors:  Henner Koch; Yvonne G Weber
Journal:  Epilepsy Behav       Date:  2018-07-31       Impact factor: 2.937

6.  Effects of the ketogenic diet in the glucose transporter 1 deficiency syndrome.

Authors:  Jörg Klepper; Sonja Diefenbach; Alfried Kohlschütter; Thomas Voit
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2004-03       Impact factor: 4.006

7.  Dominant β-catenin mutations cause intellectual disability with recognizable syndromic features.

Authors:  Valter Tucci; Tjitske Kleefstra; Andrea Hardy; Ines Heise; Silvia Maggi; Marjolein H Willemsen; Helen Hilton; Chris Esapa; Michelle Simon; Maria-Teresa Buenavista; Liam J McGuffin; Lucie Vizor; Luca Dodero; Sotirios Tsaftaris; Rosario Romero; Willy N Nillesen; Lisenka E L M Vissers; Marlies J Kempers; Anneke T Vulto-van Silfhout; Zafar Iqbal; Marta Orlando; Alessandro Maccione; Glenda Lassi; Pasqualina Farisello; Andrea Contestabile; Federico Tinarelli; Thierry Nieus; Andrea Raimondi; Barbara Greco; Daniela Cantatore; Laura Gasparini; Luca Berdondini; Angelo Bifone; Alessandro Gozzi; Sara Wells; Patrick M Nolan
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

8.  Treatment of myoclonic-atonic epilepsy caused by SLC2A1 de novo mutation with ketogenic diet: A case report.

Authors:  Zihan Wei; Luojun Wang; Yanchun Deng
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

9.  Next-generation sequencing study reveals the broader variant spectrum of hereditary spastic paraplegia and related phenotypes.

Authors:  Ewelina Elert-Dobkowska; Iwona Stepniak; Wioletta Krysa; Karolina Ziora-Jakutowicz; Maria Rakowicz; Anna Sobanska; Jacek Pilch; Dorota Antczak-Marach; Jacek Zaremba; Anna Sulek
Journal:  Neurogenetics       Date:  2019-02-19       Impact factor: 2.660

10.  Exome sequencing identifies molecular diagnosis in children with drug-resistant epilepsy.

Authors:  Mandy Ho-Yin Tsang; Gordon Ka-Chun Leung; Alvin Chi-Chung Ho; Kit-San Yeung; Christopher Chun-Yu Mak; Steven Lim-Cho Pei; Mullin Ho-Chung Yu; Anita Sik-Yau Kan; Kelvin Yuen-Kwong Chan; Karen Ling Kwong; So-Lun Lee; Ada Wing-Yan Yung; Cheuk-Wing Fung; Brian Hon-Yin Chung
Journal:  Epilepsia Open       Date:  2018-12-06
View more
  2 in total

1.  Dystonia-Deafness Syndrome: ACTB Pathogenic Variant in an Argentinean Family.

Authors:  Lucía Zavala; Gabriela Ziegler; Dolores González Morón; Nélida Garretto
Journal:  Mov Disord Clin Pract       Date:  2021-11-14

2.  Genetically altered animal models for ATP1A3-related disorders.

Authors:  Hannah W Y Ng; Jennifer A Ogbeta; Steven J Clapcote
Journal:  Dis Model Mech       Date:  2021-10-06       Impact factor: 5.732

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.